This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Generic drug maker Mylan suit over access to Celgene drugs to continue, judge rules

( December 23, 2014, 16:54 GMT | Official Statement) -- MLex Summary: US District Judge Esther Salas has refused drug maker's Celgene request that she throw out an antitrust suit over brought by rival Mylan over access to two Celgene drugs. Mylan claims that efforts to make generic versions of Thalomid and Revlimid have been frustrated by Celgene's purported abuse of safety restrictions that give it control over who has access to the drugs. Salas said that Mylan's claims under Section 2 of the Sherman Act can go forward, but dismissed claims under Section 1 that target Celgene's relationship with its distributors. The judge gave Mylan a chance to rework those claims.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections